



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ertugliflozin (Standard)

Cat. No.:	HY-15461R
CAS No.:	1210344-57-2
Molecular Formula:	C ₂₂ H ₂₅ ClO ₇
Molecular Weight:	436.88
Target:	SGLT
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC ₅₀ of 0.877 nM for h-SGLT2 ^[1] . Has the potential for the treatment of type 2 diabetes mellitus ^[2] .
IC₅₀ & Target	IC ₅₀ : 0.877 nM (h-SGLT2) ^[1] .

REFERENCES

- [1]. Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxabicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. *J Med Chem.* 2011 Apr 28;54(8):2952-60.
- [2]. Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. *Drug Metab Dispos.* 2013 Feb;41(2):445-56.
- [3]. Kalgutkar AS, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. *Drug Metab Dispos.* 2011 Sep;39(9):1609-19.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA